While previous research has shown that SRSF1 overexpression is associated with increased malignancy and drug resistance in breast cancer, our results demonstrate that CYT treatment significantly reduces SRSF1 expression in drug-resistant cells (Song et al., 2024). This evidence concerns the gene SRSF1 and breast carcinoma.